tbuckley/cabot-search huggingface dataset:
Metabolic syndrome marker profile in patients with hepatocellular carcinoma HCC.
Authors: Nil Guler, Steve Scaglione, Daneyal Syed, Danyelle Martin, Debra Hoppensteadt, Jennifer Saluk, Jasmin Sandhu, Rachel Palumbo, Thomas Layden, Omer M. Iqbal, Jawed Fareed
Journal: Journal of Clinical Oncology (2015)

e22255 Background: Metabolic syndrome (MetS) has been known to be associated with HCC; however, the biomarkers of this syndrome have not been adequately profiled. Adipokine expression profile alterations in MetS and signaling of these biomarkers may have a role in the pathogenesis of HCC. Methods: To measure markers of MetS in the presence of HCC, the Biochip Array technology (Randox-Co. Antrim, UK) was used. This chip is capable of measuring C Peptide, ferritin, IL6, resistin, insulin, TNFa, IL1a, leptin, and PAI-1 in a single blood sample. Blood samples of 31 patients with HCC and 25 healthy controls were collected under IRB approval. The HCC patients were subdivided according to treatment experienced (n = 13) or non-treated (n = 18). The non-treated HCC group was divided into two groups based a diagnosis of Diabetes Mellitus (DM); diabetic (n = 6) and not diabetic (n = 12). Correlation analysis between tumor size and expression of MetS biomarkers were performed. Data is compiled as median [IQR]. Results: The HCC patients exhibited significant increase in some of the biomarkers: ferritin 268 ng/mL [120-366] p < .0001, IL6 5.96 pg/mL [2-26] p < .0001, resistin 4.74 ng/mL [3.3-6.7] p < .0001, TNFa 8.7 pg/mL [6-10] p < .0001, IL-1a 0.49 pg/mL [0.38-0.7] p = .041 and PAI-1 8.44 ng/mL [4.7-13] p < .0001. Insulin, C peptide and leptin did not show any changes. When the HCC patients were stratified in to treated and non-treated, no difference were noted in biomarker profile except ferritin which was higher in treated group than non-treated 366.7 [269-436] vs 185.2 [101-299] p = .005. When non-treated HCC patients were stratified in DM and non-DM groups, no difference was noted in biomarker profiles. In HCC patients increased levels of resistin was correlated with IL-6 (p = .049) and IL-1a (p < .0001). Also in these patients, PAI-1 level was correlated with TNF-alpha (p = .0005). PAI-1 was the only a-marker which correlated with tumor size (r = 0.42; p = .017). Conclusions: The observed increased levels of IL-6, ferritin, TNF alpha, IL-1a, resistin and PAI-1 support the co-existence of ongoing inflammatory, fibrinolytic and metabolic derangement processes in HCC. Targeting these biomarkers may provide additional approaches for the adjunctive management of HCC.
Tissue microarray analysis on prognostic value of coexpression of RUNX3 and trimethylated histone H3 lysine 27 in surgically resected patients with stage I non-small cell lung cancer
Authors: X. Chen, Y. Deng, Y. Shi
Journal: Annals of Oncology (2019)

Background: Lung cancer is still the leading cause of cancer-related deaths in both sexes in China and worldwide. Although many surgically resected patients shared the same histology and pathologic TNM stage, their prognosis had varied a lot. For within the stage-Ipatients who had received radical surgery of lung cancer, nearly one-third of them suffered from postoperative relapse or distant metastasis. In the present study, we sought to investigate the potential interrelationships of expression of RUNX3, H3K27me3 and its methyltransferase EZH2 in NSCLC patients, their correlation with clinicopathologic parameters, and the prognostic significance as well. Methods: A total of 208 NSCLC patients and block samples who had never received other therapies before were collected and built into tissue microarrays (TMA). Protein level of RUNX3, H3K27me3, EZH2 were detected and evaluated with immunohistochemistryand western blotting to determine their expressions and mutual correlations. Results: Co-expression of RUNX3 and H3K27me3 stood a vital significance in the prediction of better outcome and longer OS in early-stage NSCLC, especially pTNM stage-I(p = 0.0124). Correlation analysis demonstrated that non-coexpression of RUNX3 and H3K27me3 was significantly associated with male sex (p = 0.037), high ECOG PS (p = 0.000), smoker (p = 0.001), postoperative relapse (p = 0.000), postoperative distant metastasis (p = 0.048), non-nuclear expression of RUNX3 (p = 0.000) and low EZH2 expression (p = 0.016) while had nothing to do with age (p = 0.918), histology (p = 0.145), BMI (p = 0.300), lymphatic vessels involvement (p = 0.246), pleural involvement (p = 0.811), vascular involvement (p = 0.144), T staging (p = 0.189), lymph node involvement (p = 0.152), mediastinal lymph node involvement (p = 0.608), M staging (p = 0.667), TNM staging (p = 0.227, p = 0.231), resectibility (p = 0.850), depth of invasion (p = 0.245), serum CEA level (p = 0.174) or Ki-67 expression (p = 0.947). Conclusions: Coexpression of RUNX3 and H3K27me3 is a good marker as survival gain to discriminiate whether or not TNM stage-INSCLC patients would have a better survival. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Personalised surveillance for serrated polyposis syndrome: results from a prospective 5-year international cohort study
Authors: Arne GC Bleijenberg, Joep EG IJspeert, Yasmijn J van Herwaarden, Sabela Carballal, María Pellisé, Gerhard Jung, Tanya M Bisseling, Iris D Nagetaal, Monique E van Leerdam, Niels van Lelyveld, Xavier Bessa, Francisco Rodríguez-Moranta, Barbara Bastiaansen, Willemijn de Klaver, Liseth Rivero, Manon CW Spaander, Jan Jacob Koornstra, Luis Bujanda, Francesc Balaguer, Evelien Dekker
Journal: Gut (2019)

Background and aims Serrated polyposis syndrome (SPS) is associated with an increased risk of colorectal cancer (CRC). International guidelines recommend surveillance intervals of 1–2 years. However, yearly surveillance likely leads to overtreatment for many. We prospectively assessed a surveillance protocol aiming to safely reduce the burden of colonoscopies. Methods Between 2013 and 2018, we enrolled SPS patients from nine Dutch and Spanish hospitals. Patients were surveilled using a protocol appointing either a 1-year or 2-year interval after each surveillance colonoscopy, based on polyp burden. Primary endpoint was the 5-year cumulative incidence of CRC and advanced neoplasia (AN) during surveillance. Results We followed 271 SPS patients for a median of 3.6 years. During surveillance, two patients developed CRC (cumulative 5-year incidence 1.3%[95% CI 0% to 3.2%]). The 5-year AN incidence was 44% (95% CI 37% to 52%), and was lower for patients with SPS type III (26%) than for patients diagnosed with type I (53%) or type I and III (59%, p&lt;0.001). Most patients were recommended a 2-year interval, and those recommended a 2-year interval were not at increased risk of AN: AN incidence after a 2-year recommendation was 15.6% compared with 24.4% after a 1-year recommendation (OR 0.57, p=0.08). Conclusion Risk stratification substantially reduced colonoscopy burden while achieving CRC incidence similar to previous studies. AN incidence is considerable in SPS patients, but extension of surveillance intervals was not associated with increased AN in those identified as low-risk by the protocol. We identified SPS type III patients as low-risk group that might benefit from even less frequent surveillance. Trial registration number The study was registered on http://www.trialregister.nl ; trial-ID NTR4609.
TCTAP A-008 Immediate Percutaneous Coronary Intervention Following Return of Spontaneous Circulation in Cardiac Arrest Due to Acute Coronary Syndrome: Single Centre Experience
Authors: Vipin Mughilassery Thomachan, Abdullah M.A. Shehab, Ahmed Siddiqui, Ali Shamsi, Gohar Jamil
Journal: Journal of the American College of Cardiology (2019)
Case 12-2019: A 60-Year-Old Man with Weakness and Difficulty Chewing
Authors: Christopher T. Doughty, Amanda C. Guidon, Sabrina Paganoni, E. Tessa Hedley-Whyte
Journal: New England Journal of Medicine (2019)

A 60-year-old man was evaluated in the neurology clinic of this hospital because of difficulty chewing and progressive, generalized weakness. Physical examination revealed atrophy and fasciculations in multiple muscle groups; a video shows examination of a similar patient.
Wireless Vital Signs Monitoring for the NICU
Authors: Jennifer Abbasi
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cost-effectiveness analysis of preoperative versus postoperative radiotherapy in resectable extremity soft tissue sarcoma.
Authors: Melody Xuan Lu Qu, Alexander V. Louie, Nabil Wasif
Journal: Journal of Clinical Oncology (2015)

10548 Background: Preoperative and postoperative radiotherapy (RT) for extremity soft tissue sarcoma (STS) have similar recurrence and overall survival outcomes. However, side effect profiles, costs and long-term functional outcomes are different. The aim of the study was to determine the optimal sequencing of RT in these patients through decision analysis. Methods: A cost-effectiveness analysis was conducted using a Markov model, with quality adjusted life years (QALYs) as the primary outcome. Utility values, rates of acute and chronic complications, transition probabilities and cost data were extracted from the published literature. Overall and progression free outcomes were internally validated. One-way and two-way sensitivity analyses were performed to determine the thresholds at which each strategy would be preferred. Probabilistic sensitivity analysis was performed for complication rates and costs to assess the robustness of this model. The time horizon was 5 years with a cycle length of 3 months. QALYs and costs were discounted at a rate of 3%. Results: Preoperative RT is a more cost effective strategy ($9,760/QALY) when compared to postoperative RT ($11,752/QALY). Preoperative RT is the preferred strategy for all acute wound complication rates tested on one-way sensitivity analysis. Postoperative RT is the preferred strategy when chronic complications with this modality is less than 17%, or when the rate seen in preoperative RT is greater than 61%. On probabilistic sensitivity analysis, preoperative RT is the preferred strategy in 75% of cases at a willingness to pay threshold of $50,000. Conclusions: Our model suggests that preoperative RT is more cost-effective than postoperative RT in the management of resectable extremity STS, primarily due to the lower incidence of chronic wound complications.
SAT-338-Oral arginine supplementation attenuates the progression of steatosis to non-alcoholic steatohepatitis through preventing translocation of bacterial endotoxin
Authors: Anja Baumann, Dragana Rajcic, Annette Brandt, Finn Jung, Anika Nier, Cheng Jun Jin, Ina Bergheim
Journal: Journal of Hepatology (2019)
TCTAP C-197 Successfully Endovascular Therapy for Bilateral Common Iliac Vein Chronic Total Occlusion: Antegrade Revascularization First for Contralateral Controlled Antegrade and Retrograde Subintimal Tracking Revascularization
Authors: Chungyu Lin, Jen-Kuang Lee
Journal: Journal of the American College of Cardiology (2019)
THU-195-An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resitance-associated substitution
Authors: Ming-Lung Yu, Chao-Hung Hung, Pin-Nan Cheng, Ming-Jong Bair, Yi-Hsiang Huang, Jia-Horng Kao, Shih-Jer Shu, Pei-Lun Lee, Jyh-Jou Chen, Rong-Nan Chien, Cheng-Yuan Peng, Chun-Yen Lin, Tsai-Yuan Hsieh, Chia-Yen Dai, Jee-Fu Huang, Chung-Feng Huang, Wan-Long Chuang
Journal: Journal of Hepatology (2019)
PS-071-Piloting of integrated HCV, TB and HIV screening model at primary care level in Georgia
Authors: Irma Khonelidze, Amiran Gamkrelidze, Maia Lagvilava, Maka Danelia, Ketevan Stvilia, Ekaterine Ruadze, Maia Tsereteli, Irina Karosanidze, Vladimer Getia, Nana Odisharia, Anzor Kobalia
Journal: Journal of Hepatology (2019)
Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation
Authors: K. Scott Baker, Wendy M. Leisenring, Pamela J. Goodman, Ralph P. Ermoian, Mary E. Flowers, G. Schoch, Rainer Storb, Brenda M. Sandmaier, H. Joachim Deeg
Journal: Blood (2019)
Screening for Breast Cancer in Average-Risk Women: A Guidance Statement From the American College of Physicians
Authors: Amir Qaseem, Jennifer S. Lin, Reem A. Mustafa, Carrie A. Horwitch, Timothy J. Wilt
Journal: Annals of Internal Medicine (2019)

The purpose of this guidance statement is to provide advice to clinicians on breast cancer screening in average-risk women based on a review of existing guidelines and the evidence they include.This guidance statement is derived from an appraisal of selected guidelines from around the world that address breast cancer screening, as well as their included evidence. All national guidelines published in English between 1 January 2013 and 15 November 2017 in the National Guideline Clearinghouse or Guidelines International Network library were included. In addition, the authors selected other guidelines commonly used in clinical practice. Web sites associated with all selected guidelines were checked for updates on 10 December 2018. The AGREE II (Appraisal of Guidelines for Research and Evaluation II) instrument was used to evaluate the quality of guidelines.The target audience is all clinicians, and the target patient population is all asymptomatic women with average risk for breast cancer.In average-risk women aged 40 to 49 years, clinicians should discuss whether to screen for breast cancer with mammography before age 50 years. Discussion should include the potential benefits and harms and a woman's preferences. The potential harms outweigh the benefits in most women aged 40 to 49 years.In average-risk women aged 50 to 74 years, clinicians should offer screening for breast cancer with biennial mammography.In average-risk women aged 75 years or older or in women with a life expectancy of 10 years or less, clinicians should discontinue screening for breast cancer.In average-risk women of all ages, clinicians should not use clinical breast examination to screen for breast cancer.
Safety and Feasibility of Using Magnetic Resonance Imaging Criteria to Identify Patients With “Good Prognosis” Rectal Cancer Eligible for Primary Surgery
Authors: Erin D. Kennedy, Marko Simunovic, Kartik Jhaveri, Richard Kirsch, Jim Brierley, Sébastien Drolet, Carl Brown, Patrick M. Vos, Wei Xiong, Tony MacLean, Selliah Kanthan, Peter Stotland, Simon Raphael, Gil Chow, Catherine A. O’Brien, Charles Cho, Cathy Streutker, Raimond Wong, Selina Schmocker, Sender Liberman, Caroline Reinhold, Neil Kopek, Victoria Marcus, Alexandre Bouchard, Caroline Lavoie, Stanislas Morin, Martine Périgny, Ann Wright, Katerina Neumann, Sharon Clarke, Nikhilesh G. Patil, Thomas Arnason, Lara Williams, Robin McLeod, Gina Brown, Alex Mathieson, Amandeep Pooni, Nancy N. Baxter
Journal: JAMA Oncology (2019)

<h3>Importance</h3> Chemoradiotherapy (CRT), followed by surgery, is the recommended approach for stage II and III rectal cancer. While CRT decreases the risk of local recurrence, it does not improve survival and leads to poorer functional outcomes than surgery alone. Therefore, new approaches to better select patients for CRT are important. <h3>Objective</h3> To conduct a phase 2 study to evaluate the safety and feasibility of using magnetic resonance imaging (MRI) criteria to select patients with "good prognosis" rectal tumors for primary surgery. <h3>Design, Setting, and Participants</h3> Prospective nonrandomized phase 2 study at 12 high-volume colorectal surgery centers across Canada. From September 30, 2014, to October 21, 2016, a total of 82 patients were recruited for the study. Participants were patients newly diagnosed as having rectal cancer with MRI-predicted good prognosis rectal cancer. The MRI criteria for good prognosis tumors included distance to the mesorectal fascia greater than 1 mm; definite T2, T2/early T3, or definite T3 with less than 5 mm of extramural depth of invasion; and absent or equivocal extramural venous invasion. <h3>Interventions</h3> Patients with rectal cancer with MRI-predicted good prognosis tumors underwent primary surgery. <h3>Main Outcomes and Measures</h3> The primary outcome was the proportion of patients with a positive circumferential resection margin (CRM) rate. Assuming a 10% baseline probability of a positive CRM, a sample size of 75 was estimated to yield a 95% CI of ±6.7%. <h3>Results</h3> Eighty-two patients (74% male) participated in the study. The median age at the time of surgery was 66 years (range, 37-89 years). Based on MRI, most tumors were midrectal (65% [n = 53]), T2/early T3 (60% [n = 49]), with no suspicious lymph nodes (63% [n = 52]). On final pathology, 91% (n = 75) of tumors were T2 or greater, 29% (n = 24) were node positive, and 59% (n = 48) were stage II or III. The positive CRM rate was 4 of 82 (4.9%; 95% CI, 0.2%-9.6%). <h3>Conclusions and Relevance</h3> The use of MRI criteria to select patients with good prognosis rectal cancer for primary surgery results in a low rate of positive CRM and suggests that CRT may not be necessary for all patients with stage II and III rectal cancer. <h3>Trial Registration</h3> ISRCTN.com identifier:ISRCTN05107772
Letter to the Editor: The Evaluation of cGAS–STING Pathway Expression In Vivo
Authors: Mingyuan Zhang
Journal: Hepatology (2019)

Potential conflict of interest: Nothing to report. To the Editor: We read the recent article by Verrier et al. with great interest.1 The authors have shown that Cyclic GMP‐AMP Synthase (cGAS) is expressed in the human liver, primary human hepatocytes, and human liver chimeric mice. Also, unencapsidated, relaxed circular hepatitis B virus (HBV) DNA was sensed by cGAS‐dependent manner in hepatoma cell lines and primary human hepatocytes; however, the host cell recognition of viral nucleic acids was found to be abolished during HBV infection, suggesting that HBV exploits multiple strategies to evade sensing and antiviral activity of cGAS and its effector pathways. Nonetheless, we have some doubts. We think that more in vivo chimeric mouse experiments should be performed. In this research, in vitro expression of interferon was detected, whereas in the chimeric mouse model, only MB21D1 was tested; this is not considered to be a complete design, as studies have shown that the cGAS‐stimulator of interferogenes (STING) pathway is not the only one that is responsible for innate immune signaling.2 Also, in the in vivo experiments, we hope the author can discuss whether there are other innate immune signaling pathways that are activated after HBV infection. Apart from hepatocytes, there are other cells in the liver that are usually involved in the immune response, such as Kupffer cells, in which the corresponding cGAS–STING signaling pathway might also be activated, resulting in interferon production. During an acute HBV infection, patients often present with clinical symptoms. These symptoms typically include elevated alanine aminotransferase (ALT),3 which represents the activation of the immune system that is responsible for HBV clearance. In the mouse model of this study, the researchers only described the liver function of mice based on albumin levels, but we consider the description of ALT to also be important. It would be beneficial if the authors could provide data on the ALT levels from the mouse experiments.
SAT-295-Diagnostic accuracy of non-invasive Methods (NFS Score and FIB-4) for detecting advanced fibrosis: Avalidation study of NFS score and FIB-4 in a cohort of South Indian patients with NAFLD
Authors: Charles Panackel, Mathew Jacob, Joe Francis, Kaiser Raja, Mallikarjun Sakpal, Naveen Ganjoo, Sonal Asthana, Rajiv Lochan, Rehan Saif, Jayanth Reddy, Ismail Siyad, Ganesh Ramesh, Rommel Sandhyav, Noushif m
Journal: Journal of Hepatology (2019)
Up-regulation of CALR in patients with essential thrombocythemia independent from CALR mutations.
Authors: Ciro Roberto Rinaldi, Lillia BROWN, Ciaren Graham, Rachael Simpson, James Lally
Journal: Journal of Clinical Oncology (2015)

7086 Background: Somatic mutations in the exon 9 of calreticulin (CALR) gene were recently discovered in patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF) lacking JAK2 and MPL mutations, and absent in patient with polycythemia vera (PV). Among patients with ET or PMF with un-mutated JAK2 or MPL, CALR mutations were detected in 67% of those with ET and 88% of those with primary PMF. Over expression of the most frequent CALR deletion caused cytokine-independent growth in vitro owing to the activation of signal transducer and activator of transcription 5 (STAT5) by means of an unknown mechanism. Patients with myeloproliferative neoplasms carrying CALR mutations presented with higher platelet counts and lower hemoglobin levels than patients with mutated JAK2, but also a lower risk of thrombosis and longer overall survival than patients with mutated JAK2. Methods: We analyzed by Real Time PCR, CALR expression in peripheral blood (PB) of 38 patients affected by ET, 17 JAK2 mutated (45 %), 4 CALR (10.5%) mutated, 1 MPL mutated (3%) and 14 with no molecular abnormalities, and compared with a cohort of healthy volunteers. Results: We found a significant over expression of CALR (median 5.15; range 1.13-270.08 ) comparing with controls (median 0.38, range 0.18-1).No significant difference was found comparing CALR expression in CALR mutated (median 4.9, range 1.51-37.14) and CALR/JAK2 un-mutated patients (4.68, range 1.51-28.71). CALR up-regulation is not mutually exclusive with JAK2 mutations, there was, in fact, no difference in CALR mRNA between JAK2 mutated (median 5.09, range 1.13-270) and wild type ET patients (median 5.08, range 1.51-37). There was no significant difference when we correlated CALR expression with PLT counts, spleen size or type of cytoreductive therapy. Conclusions: CALR mRNA expression is independent from the CALR mutational status and more interestingly is up-regulated also in JAK2 mutated patients. A larger cohort of patients is required to confirm these preliminary findings.